How to switch from mirtazapine to Cymbalta (duloxetine) after 2 weeks?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Switching from Mirtazapine 15mg to Duloxetine After 2 Weeks

After only 2 weeks of mirtazapine 15mg, you can safely perform a direct cross-taper over 1-2 weeks: start duloxetine 30mg daily while simultaneously tapering mirtazapine by 50% (to 7.5mg) for 3-7 days, then stop mirtazapine and increase duloxetine to 60mg daily after the first week. 1, 2

Rationale for This Approach

The short duration of mirtazapine treatment (only 2 weeks) significantly reduces the risk of severe withdrawal symptoms, though discontinuation reactions can still occur even after brief exposure. 3, 4 A conservative cross-taper minimizes both withdrawal risk and the gap in antidepressant coverage that could worsen depression. 5

Step-by-Step Switching Protocol

Week 1 of Transition:

  • Day 1-7: Start duloxetine 30mg once daily in the morning (lower starting dose reduces nausea risk) 1, 2
  • Day 1-3: Continue mirtazapine 15mg at bedtime 5
  • Day 4-7: Reduce mirtazapine to 7.5mg at bedtime (50% reduction) 5, 6

Week 2 of Transition:

  • Day 8 onward: Stop mirtazapine completely 5
  • Day 8 onward: Increase duloxetine to 60mg once daily (the standard therapeutic dose) 1, 2

Critical Safety Monitoring

Monitor closely for withdrawal symptoms during days 2-5 after stopping mirtazapine, as symptom onset is typically acute and presents within 48 hours of discontinuation. 4 Common withdrawal symptoms include:

  • Anxiety, agitation, or panic-like symptoms 3, 4
  • Nausea and loss of appetite 4
  • Tremor and dizziness 3
  • Sleep disturbances 3

If severe withdrawal symptoms develop, consider restarting mirtazapine briefly and tapering more gradually over 2-3 weeks instead. 3, 4

Duloxetine-Specific Considerations

Duloxetine has significant advantages over other SNRIs (like venlafaxine) in terms of cardiovascular safety—it does not cause blood pressure elevation or cardiac conduction abnormalities, making it safer and requiring no cardiac monitoring. 1, 2

The 30mg starting dose for one week is essential to minimize nausea, which is the most common early side effect. 1, 2 Taking duloxetine with food can further reduce gastrointestinal symptoms.

The target dose of 60mg once daily is effective for depression, anxiety, and pain conditions—higher doses provide no additional benefit but increase side effects. 2

Follow-Up Timeline

  • Week 1: Contact patient mid-week to assess mirtazapine withdrawal symptoms and duloxetine tolerability 7
  • Week 2: Assess response to dose increase and monitor for nausea or other side effects 1
  • Week 4-6: Evaluate therapeutic response to duloxetine at full dose 1, 7

Important Caveats

Never combine mirtazapine or duloxetine with MAOIs—ensure no MAOI use in the past 14 days before starting this switch. 7

Abrupt discontinuation of mirtazapine should be avoided even after short-term use, as case reports document severe panic attacks and withdrawal syndromes occurring after only 10 weeks of treatment when stopped suddenly. 3

When eventually discontinuing duloxetine in the future, it must also be tapered gradually over weeks to months to avoid SNRI discontinuation syndrome. 1, 2, 6

This cross-taper approach is safer than abrupt switching because it maintains some antidepressant coverage throughout the transition, reducing the risk of depressive relapse while minimizing withdrawal symptoms. 5

References

Guideline

Switching from Sertraline to Duloxetine or Venlafaxine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guidelines for Using Duloxetine in the Elderly Population

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The Hunger for Mirtazapine: A Discontinuation Syndrome.

Journal of pain & palliative care pharmacotherapy, 2021

Research

Switching and stopping antidepressants.

Australian prescriber, 2016

Guideline

Transitioning from Venlafaxine to Sertraline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.